449 related articles for article (PubMed ID: 33431716)
21. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
22. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
23. Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events.
Sakuma M; Iimuro S; Shinozaki T; Kimura T; Nakagawa Y; Ozaki Y; Iwata H; Miyauchi K; Daida H; Suwa S; Sakuma I; Nishihata Y; Saito Y; Ogawa H; Matsuzaki M; Ohashi Y; Taguchi I; Toyoda S; Inoue T; Nagai R
BMC Med; 2022 Nov; 20(1):441. PubMed ID: 36372869
[TBL] [Abstract][Full Text] [Related]
24. Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Nakazawa M; Arashi H; Yamaguchi J; Ogawa H; Hagiwara N
Atherosclerosis; 2020 Jun; 303():21-28. PubMed ID: 32474302
[TBL] [Abstract][Full Text] [Related]
25. Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial.
Miyauchi K; Kimura T; Shimokawa H; Daida H; Iimuro S; Iwata H; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Ohashi Y; Ohtsu H; Saito Y; Matsuzaki M; Nagai R;
Int Heart J; 2018 Mar; 59(2):315-320. PubMed ID: 29503404
[TBL] [Abstract][Full Text] [Related]
26. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.
Lama S; Souraya D; Youssef F
Int J Clin Pharm; 2017 Aug; 39(4):919-926. PubMed ID: 28523462
[TBL] [Abstract][Full Text] [Related]
27. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention.
Seo SM; Choo EH; Koh YS; Park MW; Shin DI; Choi YS; Park HJ; Kim DB; Her SH; Lee JM; Park CS; Kim PJ; Moon KW; Chang K; Kim HY; Yoo KD; Jeon DS; Chung WS; Park YG; Seung KB;
Heart; 2011 Dec; 97(23):1943-50. PubMed ID: 21665885
[TBL] [Abstract][Full Text] [Related]
28. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL.
Fujihara Y; Nakamura T; Horikoshi T; Obata JE; Fujioka D; Watanabe Y; Watanabe K; Kugiyama K
Circ J; 2019 May; 83(6):1302-1308. PubMed ID: 30996151
[TBL] [Abstract][Full Text] [Related]
29. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
[TBL] [Abstract][Full Text] [Related]
30. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
[TBL] [Abstract][Full Text] [Related]
31. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
32. Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease.
Ishii J; Kashiwabara K; Ozaki Y; Takahashi H; Kitagawa F; Nishimura H; Ishii H; Iimuro S; Kawai H; Muramatsu T; Naruse H; Iwata H; Tanizawa-Motoyama S; Ito H; Watanabe E; Matsuyama Y; Fukumoto Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Hokimoto S; Miyauchi K; Ohtsu H; Izawa H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Matsuzaki M; Nagai R
J Atheroscler Thromb; 2022 Oct; 29(10):1458-1474. PubMed ID: 34880156
[TBL] [Abstract][Full Text] [Related]
33. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
34. Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes.
Jin JL; Zhang HW; Cao YX; Liu HH; Hua Q; Li YF; Zhang Y; Guo YL; Wu NQ; Zhu CG; Xu RX; Gao Y; Li XL; Cui CJ; Liu G; Sun J; Dong Q; Santos R; Li JJ
Cardiovasc Diabetol; 2020 Sep; 19(1):152. PubMed ID: 32981521
[TBL] [Abstract][Full Text] [Related]
35. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
36. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk.
Toth PP; Granowitz C; Hull M; Liassou D; Anderson A; Philip S
J Am Heart Assoc; 2018 Aug; 7(15):e008740. PubMed ID: 30371242
[TBL] [Abstract][Full Text] [Related]
37. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
38. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
Acharjee S; Boden WE; Hartigan PM; Teo KK; Maron DJ; Sedlis SP; Kostuk W; Spertus JA; Dada M; Chaitman BR; Mancini GB; Weintraub WS
J Am Coll Cardiol; 2013 Nov; 62(20):1826-33. PubMed ID: 23973693
[TBL] [Abstract][Full Text] [Related]
39. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
[TBL] [Abstract][Full Text] [Related]
40. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.
Ogita M; Miyauchi K; Miyazaki T; Naito R; Konishi H; Tsuboi S; Dohi T; Kasai T; Yokoyama T; Okazaki S; Kurata T; Daida H
Heart Vessels; 2014 Jan; 29(1):35-41. PubMed ID: 23516028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
